Kynurenic acid Polyclonal Antibody
Ref: IS1011
IFIHCKynurenine pathwayTryptophan metabolismPolyclonal AntibodiesICC

Kynurenic acid detection in human caudate putamen by IHC
Immunohistochemistry (IHC) reveals kynurenic acid accumulation in the cytoplasm of glial cells in human caudate putamen. Paraffin-embedded brain tissue section was subjected to pH=6 antigen retrieval followed by overnight incubation with the primary anti-kynurenic acid polyclonal antibody (dilution 1/2000). After incubation with polymer-conjugated secondary Ab, DAB was used to visualize the staining.
DatasheetMSDS
The anti-Kynurenic acid (KYNA) rabbit polyclonal antibody proved to work at 1/2000 dilution on paraffin-embedded tissues, a single vial thus catering for approximately 400 stainings.
Clonality | Polyclonal antibody |
Host | Rabbit |
Valided applications | IHC |
Reactivity | Reacts with all species |
References | Not yet cited to our knowledge. Submit content and get a 10% discount! |
Format | 50µl |
Size | 50µg |
---|
440.00€
99 in stock
Worldwide shipping
Product overview
Product name | Kynurenic acid polyclonal antibody |
Synonyms | Kinurenic acid polyclonal antibody
4-Hydroxyquinoline-2-carboxylic acid polyclonal antibody KYNA polyclonal antibody |
Immunogen | Conjugated kynurenic acid |
Specificity | When tested in competitive ELISA, the anti-Kynurenic polyclonal antibody did not show any significant cross reactivity with Quinaldic and Xanthurenic conjugates |
Storage
Form | Liquid |
Purity | Purified anti-serum |
Storage | Store at +4°C for short term (1-2 months). Aliquot and store at -20°C for long term. Avoid repeated freeze / thaw cycles |
Material safety datasheet | Download MSDS |
Immunohistochemistry (IHC) | Dilute at 1:200-1:2000. Perform heat antigen retrieval (pH=6) before initiating IHC staining protocol on paraffin-embedded and frozen sections |
Comments | Optimal working dilutions must be determined by the end-user |
Restrictions | For research use only |
Antibody not yet cited. Submit an article and get a 10% discount.
Selected articles on Kynurenic acid:
- Justinova Z et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci. 2013 Nov;16(11):1652-61. doi: 10.1038/nn.3540. Epub 2013 Oct 13.
- Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013 Feb;34(2):136-43. doi: 10.1016/j.tips.2012.09.006. Epub 2012 Nov 1.
- Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012 Jul;13(7):465-77. doi: 10.1038/nrn3257.
- Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 2012 Feb;119(2):133-9. doi: 10.1007/s00702-011-0763-x. Epub 2012 Jan 4.
- Linderholm KR et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012 May;38(3):426-32. doi: 10.1093/schbul/sbq086. Epub 2010 Aug 20.
- Stone TW, Forrest CM, Darlington LG. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012 Apr;279(8):1386-97. doi: 10.1111/j.1742-4658.2012.08487.x. Epub 2012 Mar 27.